New Market Report Forecasts Implanted Pain Neuromodulation

Staff report

September 2023 issue

Neurotech Reports, the publisher of this newsletter, released a newly revised market research report detailing the implanted pain neuromodulation device industry. The report, titled The Market for Implanted Pain Neuromodulation Systems: 2023-2028, estimates that the total worldwide market for implanted pain neuromodulation systems will grow from $2.66 billion in 2023 to $5.88 billion in 2028.

The new report breaks down the market by U.S. and OUS forecasts for both implanted spinal cord stimulation systems and implanted peripheral nerve stimulation systems. It also forecasts share of market for both SCS and PNS vendors in 2023, 2025, and 2028. The leading SCS vendors are currently Boston Scientific, Abbott, Medtronic, and Nevro, though new players like Saluda Medical and Biotronik Neuro will have a growing impact on the market. In the PNS space, the major players are SPR Therapeutics, Nalu Medical, Bioventus, and Curonix, though several new players are on the horizon.

Other key features of the new report are in-depth analyses of key technology and market factors impacting both SCS and PNS vendors, detailed descriptions of all competitors, including publicly traded and privately held firms, and coverage of recent developments at key industry conferences such as the North American Neuromodulation Society meeting, The Napa Pain Conference, and the American Society of Pain and Neuroscience.

The Market for Implanted Pain Neuromodulation Systems: 2023-2028 is available immediately from Neurotech Reports for $2495 for the single-reader version, $3295 for a two- to five-reader version, and $4595 for a six- to 10-reader version. The report is also available at no extra cost for Premium subscribers to Neurotech Business Report.

For more information on The Market for Implanted Pain Neuromodulation Systems: 2023-2028 visit this link.